Literature DB >> 16647992

Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2).

Andrea L Gropman1, Wallace C Duncan, Ann C M Smith.   

Abstract

The Smith-Magenis syndrome is a rare, complex multisystemic disorder featuring, mental retardation and multiple congenital anomalies caused by a heterozygous interstitial deletion of chromosome 17p11.2. The phenotype of Smith-Magenis syndrome is characterized by a distinct pattern of features including infantile hypotonia, generalized complacency and lethargy in infancy, minor skeletal (brachycephaly, brachydactyly) and craniofacial features, ocular abnormalities, middle ear and laryngeal abnormalities including hoarse voice, as well as marked early expressive speech and language delays, psychomotor and growth retardation, and a 24-hour sleep disturbance. A striking neurobehavioral pattern of stereotypies, hyperactivity, polyembolokoilamania, onychotillomania, maladaptive and self-injurious and aggressive behavior is observed with increasing age. The diagnosis of Smith-Magenis syndrome is based upon the clinical recognition of a constellation of physical, developmental, and behavioral features in combination with a sleep disorder characterized by inverted circadian rhythm of melatonin secretion. Many of the features of Smith-Magenis syndrome are subtle in infancy and early childhood, and become more recognizable with advancing age. Infants are described as looking "cherubic" with a Down syndrome-like appearance, whereas with age the facial appearance is that of relative prognathism. Early diagnosis requires awareness of the often subtle clinical and neurobehavioral phenotype of the infant period. Speech delay with or without hearing loss is common. Most children are diagnosed in mid-childhood when the features of the disorder are most recognizable and striking. While improvements in cytogenetic analysis help to bring cases to clinical recognition at an earlier age, this review seeks to increase clinical awareness about Smith-Magenis syndrome by presenting the salient features observed at different ages including descriptions of the neurologic and behavioral features. Detailed review of the circadian rhythm disturbance unique to Smith-Magenis syndrome is presented. Suggestions for management of the behavioral and sleep difficulties are discussed in the context of the authors' personal experience in the setting of an ongoing Smith-Magenis syndrome natural history study.

Entities:  

Mesh:

Year:  2006        PMID: 16647992     DOI: 10.1016/j.pediatrneurol.2005.08.018

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  39 in total

1.  Smith-Magenis Syndrome: Face Speaks.

Authors:  Rekha Gupta; Neerja Gupta; Sheela Nampoothiri; Kausik Mandal; Yougal Kishore; Pankaj Sharma; Madhulika Kabra; Shubha R Phadke
Journal:  Indian J Pediatr       Date:  2015-12-17       Impact factor: 1.967

Review 2.  Yin-yang actions of histone methylation regulatory complexes in the brain.

Authors:  Patricia Marie Garay; Margarete Aryanka Wallner; Shigeki Iwase
Journal:  Epigenomics       Date:  2016-11-18       Impact factor: 4.778

3.  Brief Report: Contrasting Profiles of Everyday Executive Functioning in Smith-Magenis Syndrome and Down Syndrome.

Authors:  Lucy Wilde; Chris Oliver
Journal:  J Autism Dev Disord       Date:  2017-08

4.  Abnormal circadian rhythm of melatonin in Smith-Magenis syndrome patients with RAI1 point mutations.

Authors:  Philip M Boone; Russel J Reiter; Daniel G Glaze; Dun-Xian Tan; James R Lupski; Lorraine Potocki
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

Review 5.  Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes.

Authors:  Juanita Neira-Fresneda; Lorraine Potocki
Journal:  J Pediatr Genet       Date:  2015-09-28

6.  Genetic counseling, activism and 'genotype-first' diagnosis of developmental disorders.

Authors:  Daniel Navon
Journal:  J Genet Couns       Date:  2012-07-21       Impact factor: 2.537

7.  Reciprocal deletion and duplication of 17p11.2-11.2: Korean patients with Smith-Magenis syndrome and Potocki-Lupski syndrome.

Authors:  Cha Gon Lee; Sang-Jin Park; Jun-No Yun; Shin-Young Yim; Young Bae Sohn
Journal:  J Korean Med Sci       Date:  2012-12-07       Impact factor: 2.153

8.  Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities.

Authors:  J C Hodge; E Mitchell; V Pillalamarri; T L Toler; F Bartel; H M Kearney; Y S Zou; W H Tan; C Hanscom; S Kirmani; R R Hanson; S A Skinner; R C Rogers; D B Everman; E Boyd; C Tapp; S V Mullegama; D Keelean-Fuller; C M Powell; S H Elsea; C C Morton; J F Gusella; B DuPont; A Chaubey; A E Lin; M E Talkowski
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

9.  Circadian abnormalities in mouse models of Smith-Magenis syndrome: evidence for involvement of RAI1.

Authors:  Melanie Lacaria; Wenli Gu; James R Lupski
Journal:  Am J Med Genet A       Date:  2013-05-23       Impact factor: 2.802

10.  Review of disrupted sleep patterns in Smith-Magenis syndrome and normal melatonin secretion in a patient with an atypical interstitial 17p11.2 deletion.

Authors:  Eilis A Boudreau; Kyle P Johnson; Angela R Jackman; Jan Blancato; Marjan Huizing; Claude Bendavid; Marypat Jones; Settara C Chandrasekharappa; Alfred J Lewy; Ann C M Smith; R Ellen Magenis
Journal:  Am J Med Genet A       Date:  2009-07       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.